In ₹ Crore except Per Share Latest Annual | GLAND FY26 | DIVISLAB FY26 | AUROPHARMA FY26 | PPLPHARMA FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 47.31× | 97.31× | ◆ 27.61× | — | 62.46× -24% | |
| P/B | 4.69× | 14.89× | ◆ 2.55× | 3.45× | 3.45× +36% | |
| EV/EBITDA | 27.91× | 72.47× | ◆ 14.10× | 35.05× | 35.05× -20% | |
| Market Cap | ₹48,604 Cr | ₹2.49L Cr | ₹96,761 Cr | ₹28,134 Cr | ₹96,761 Cr -50% | |
| Growth | ||||||
| Revenue CAGR 3Y | ◆ 21.06% | 10.78% | 10.63% | 7.79% | 10.63% +98% | |
| Revenue CAGR 5Y | ◆ 13.18% | 8.67% | 6.32% | — | 7.50% +76% | |
| Net Income CAGR 3Y | 9.57% | 12.09% | ◆ 22.03% | — | 17.06% -44% | |
| Revenue YoY (latest Q) | 19.57% | ◆ 27.80% | 16.30% | 17.39% | 17.39% +13% | |
| Net Income YoY (latest Q) | 47.09% | ◆ 65.50% | 25.22% | 15.07% | 25.22% +87% | |
| Profitability | ||||||
| EBITDA Margin | 25.34% | ◆ 32.59% | 20.34% | 10.39% | 20.34% +25% | |
| Net Income Margin | 15.98% | ◆ 24.32% | 10.41% | -3.68% | 10.41% +54% | |
| Return on Common Equity | 9.92% | ◆ 15.32% | 9.25% | -3.99% | 9.25% +7% | |
| Return on Capital Employed | 11.06% | ◆ 16.55% | 12.52% | 0.68% | 12.52% -12% | |
| Return on Assets | 8.21% | ◆ 12.82% | 5.99% | -1.81% | 5.99% +37% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.02× | ◆ 0.00× | 0.20× | 0.67× | 0.20× -90% | |
| Interest Coverage | 36.24× | ◆ 129.48× | 13.20× | 0.27× | 13.20× +175% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹6,431 Cr | ₹10,560 Cr | ₹33,653 Cr | ₹8,869 Cr | ₹10,560 Cr -39% | |
| Net Income | ₹1,027 Cr | ₹2,568 Cr | ₹3,503 Cr | −₹326 Cr | ₹2,568 Cr -60% | |
| Total Assets | ₹12,511 Cr | ₹20,033 Cr | ₹58,502 Cr | ₹17,965 Cr | ₹20,033 Cr -38% | |
| EPS | ₹62.35 | ₹96.75 | ₹60.34 | ₹-2.46 | ₹60.34 +3% | |
| Book Value per Share | ₹628.67 | ₹632.49 | ₹652.25 | ₹61.5 | ₹632.49 -1% | |